Nurix Therapeutics, Inc.

Historical 13F Holders

Symbol
NRIX
CUSIP
67080M103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 67080M103 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 8.2% 4/23/2025
Event 3/31/2025
Vestal Point Capital, LP 13G/A
7.8% 8/14/2026
Event 6/30/2026
Deep Track Capital, LP 13G/A
7.5% 8/14/2026
Event 6/30/2026
Baker Bros. Advisors LP 13G/A
7.2% 2/17/2026
Event 12/31/2025
Rubric Capital Management LP 13G
7.0% 8/14/2026
Event 6/30/2026
FMR LLC 13G
5.4% 5/6/2026
Event 3/31/2026
Perceptive Advisors LLC 13G
5.3% 9/23/2026
Event 9/16/2026
Price T Rowe Associates Inc /MD/ 13G 5.3% 8/14/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.0% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Redmile Group, LLC 13G/A
8.1%
Checked 5% or less
8/14/2026
Event 6/30/2026
Commodore Capital LP 13G/A
4.9% 11/14/2025
Event 9/30/2025
Wellington Management Group LLP 13G/A
4.2% 5/12/2025
Event 3/31/2025
ARK Investment Management LLC 13G/A 0% 1/10/2025
Event 9/30/2024
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 5.42 k $128 k
2026 Q2 220 119 M $2.91 B
2026 Q1 202 117 M $1.82 B
2025 Q4 191 114 M $2.15 B
2025 Q3 179 84.8 M $784 M
2025 Q2 170 88.4 M $1.01 B
2025 Q1 176 84.6 M $1.01 B
2024 Q4 182 81.1 M $1.53 B
2024 Q3 180 68.0 M $1.53 B
2024 Q2 184 67.0 M $1.40 B
2024 Q1 148 54.2 M $796 M
2023 Q4 137 49.5 M $511 M
2023 Q3 133 44.8 M $352 M
2023 Q2 132 43.6 M $436 M
2023 Q1 128 42.5 M $377 M
2022 Q4 126 45.2 M $496 M
2022 Q3 123 43.1 M $561 M
2022 Q2 111 45.3 M $573 M
2022 Q1 122 40.4 M $567 M
2021 Q4 129 40.5 M $1.17 B
2021 Q3 116 39.5 M $1.18 B
2021 Q2 105 39.5 M $1.05 B
2021 Q1 103 41.3 M $1.29 B
2020 Q4 69 33.1 M $1.09 B
2020 Q3 67 31.9 M $1.11 B